摘要
肿瘤细胞产生抗药性的机制有几种,包括增加抗凋亡、增加药物外排
关键词: 共给药,癌症治疗,脂质体,药物,基因,协同效应。
Current Medicinal Chemistry
Title:Cancer Treatment with Liposomes Based Drugs and Genes Co-delivery Systems
Volume: 25 Issue: 28
关键词: 共给药,癌症治疗,脂质体,药物,基因,协同效应。
摘要: There are several mechanisms by which cancer cells develop resistance to treatments, including increasing anti-apoptosis, increasing drug efflux, inducing angiogenesis, enhancing DNA repair and altering cell cycle checkpoints. The drugs are hard to reach curative effects due to these resistance mechanisms. It has been suggested that liposomes based co-delivery systems, which can deliver drugs and genes to the same tumor cells and exhibit synergistic anti-cancer effects, could be used to overcome the resistance of cancer cells. As the co-delivery systems could simultaneously block two or more pathways, this might promote the death of cancer cells by sensitizing cells to death stimuli. This article provides a brief review on the liposomes based co-delivery systems to overcome cancer resistance by the synergistic effects of drugs and genes. Particularly, the synergistic effects of combinatorial anticancer drugs and genes in various cancer models employing multifunctional liposomes based co-delivery systems have been discussed. This review also gives new insights into the challenges of liposomes based co-delivery systems in the field of cancer therapy, by which we hope to provide some suggestions on the development of liposomes based co-delivery systems.
Export Options
About this article
Cite this article as:
Cancer Treatment with Liposomes Based Drugs and Genes Co-delivery Systems, Current Medicinal Chemistry 2018; 25 (28) . https://dx.doi.org/10.2174/0929867325666180111093937
DOI https://dx.doi.org/10.2174/0929867325666180111093937 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions
Current Medicinal Chemistry Modulation of pRb/E2F Functions in the Regulation of Cell Cycle and in Cancer
Current Cancer Drug Targets Prediction and Monitoring of Therapeutic Response by Molecular Imaging
Current Medical Imaging A Machine Learning-based Diagnosis of Thyroid Cancer Using Thyroid Nodules Ultrasound Images
Current Bioinformatics Targeting Strategies for Renal Cancer Stem Cell Therapy
Current Pharmaceutical Design Chelating Systems for 99mTc/188Re in the Development of Radiolabeled Peptide Pharmaceuticals
Anti-Cancer Agents in Medicinal Chemistry Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry Role of Hexokinase and VDAC in Neurological Disorders
Current Molecular Pharmacology Natural Small Molecules as Stabilizers and Activators of Cancer-Associated NQO1 Polymorphisms
Current Drug Targets Circulating Biomarkers for Tumor Angiogenesis: Where Are We?
Current Medicinal Chemistry Docetaxel/2-Hydroxypropyl β -Cyclodextrin Inclusion Complex Increases Docetaxel Solubility and Release from a Nanochannel Drug Delivery System
Current Drug Targets Development of Gel-Core Solid Lipid Nanoparticles as Drug Delivery Systems for Hydrophilic Molecules
Current Nanoscience Targeting Apoptotic Signaling Pathways in Human Lung Cancer
Current Cancer Drug Targets Patent Selections
Recent Patents on Biotechnology Recent Advances in Understanding and Exploiting the Activation of Anthracyclines by Formaldehyde
Current Medicinal Chemistry - Anti-Cancer Agents Nano-soldiers Ameliorate Silibinin Delivery: A Review Study
Current Drug Delivery Editorial [Hot Topic: Cyclooxygenase-2 Inhibitors and Cancer (Guest Editor: J.-P. Henichart)]
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Potential of Inhibiting Brutons Tyrosine Kinase, (BTK)
Current Pharmaceutical Design Retraction Notice: Protein Identification in Sub Proteome Fractions of Breast Cancer Cells by OFFGEL-IEF and iTRAQ Labeling
Current Proteomics Emerging Role of Apelin as a Therapeutic Target in Cancer: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery